Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 745-758

  Weisler, Richard H ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Methylphenidate; Mixed amfetamine salts; Pscyhostimulants

Indexed keywords

AMPHETAMINE; ANTACID AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; FOCALIN XR; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; SHORT ACTING DRUG; SPANSULE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DECREASED APPETITE; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; HUMAN; INJECTION SITE IRRITATION; INSOMNIA; IRRITABILITY; LIVER INJURY; LIVER TOXICITY; NERVOUSNESS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP TIME; SUICIDAL IDEATION; SYMPTOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; TREATMENT OUTCOME;

EID: 34247890181     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.745     Document Type: Review

References (77)

1. AMERICAN ACADEMY OF PEDIATRICS: Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics (2000) 105(5):1158-1170.
2. WEISS M, MURRAY C: Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ (2003) 168(6):715-722.
3. KESSLER RC, ADLER L, BARKLEY R et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry (2006) 163(4):716-723.
4. BARKLEY RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63(Suppl. 12):10-15.
5. BIEDERMAN J, MONUTEAUX MC, MICK E et al.: Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol. Med. (2006) 36(2):167-179.
6. GREENHILL LL, PLISZKA S, DULCAN MK et al. FOR THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY: practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry. (2002) 41(2 Suppl.):26S-49S.
7. DOPFNER M, GERBER WD, BANASCHEWSKI T et al.: Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur. Child Adolesc. Psychiatry (2004) 13(Suppl. 1):I93-I101.
8. WILENS TE, GIGNAC M, SWEZEY A et al.: Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45(4):408-414.
9. BRIGHT GM, DELPHIA B: Survey evaluation of the abuse potential of short-acting versus long-acting stimulants in ADHD [poster]. 159th American Psychiatric Association Annual Meeting. Toronto, Canada (May 24 2006) NR757
10. TETER CJ, MCCABE SE, LAGRANGE K, CRANFORD JA, BOYD CJ: Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy (2006) 26(10):1501-1510
11. SANCHEZ RJ, CRISMON ML, BARNER JC et al.: Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy (2005) 25(7):909-917.
12. PERWIEN A, HALL J, SWENSEN A, SWINDLER: Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J. Manag. Care Pharm. (2004) 10(2):122-129.
13. Ritalin LA® Prescribing Information: Novartis Pharmaceuticals Corporation. East Hanover, NJ (2006).
14. WANG Y, LEE L, SOMMA R et al.: In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Biopharm. Drug Dispos. (2004) 25(2):91-98.
15. Metadate CD® Prescribing Information: CellTech Pharma Ltd, Rochester, NY (2003).
16. ROCHDI M, GONZALEZ MA, DIRKSEN SJ: Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int. J Clin. Pharmacol. Ther. (2004) 42(5):285-292.
17. GONZALEZ MA, PENTIKIS HS, ANDERL N et al.: Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther. (2002) 40(4):175-184.
18. STEIN MA, SARAMPOTE CS, WALDMAN ID et al.: A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics (2003) 112:e404-e413.
19. SRINIVAS NR, HUBBARD JW, QUINN D, MIDHA KK: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. (1992) 52(5):561-568.
20. QUINN D, WIGAL S, SWANSON J et al.: Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(11):1422-1429.
21. Daytrana® Prescribing Information: Shire US, Inc., Wayne, PA (2006).
22. BIEDERMAN J, QUINN D, WEISS M et al.: Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr. Drugs (2003) 5(12):833-841.
23. SONUGA-BARKE EJ, SWANSON JM, COGHILL D et al.: Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry (2004) 4:28.
24. HOARE P, REMSCHMIDT H, MEDORI R et al.: 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/ hyperactivity disorder switched from MPH. (Eur. Child Adolesc.Psychiatry2005) 14(6):3 05-309.
25. WILENS TE, McBURNETT K, BUKSTEIN O et al.: Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. (2006) 160(1):82-90.
26. BIEDERMAN J, MICK E, SURMAN C et al.: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry (2006) 59(9):829-835.
27. GREENHILL LL, BALL R, LEVINE AJ et al.: Dexmethylphenidate extended release in children and adolescents with ADHD [poster]. 158th American Psychiatric Association Annual Meeting. Atlanta, GA, USA (May 21-26 2005) NR499.
28. SILVA RR,WANG J, LOPEZ F et al.: Crossover study of dexmethylphenidate extended release [poster]. 158th American Psychiatric Association Annual Meeting. Atlanta, GA, USA. (May 21-26 2005) NR489
29. ADLER LA, MCGOUGH J, MUNIZ R et al.: Long-term efficacy of extended release dexmethylphenidate in adult ADHD [poster]. 158th American Psychiatric Association Annual Meeting. Atlanta, GA, USA (May 21-26 2005) NR493.
30. MCGOUGH JJ, WIGAL SB, ABIKOFF H et al.: A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J. Atten. Disord. (2006) 9(3):476-485.
31. MELMED R, FINDLING RL, LOPEZ FA: The effects of transdermal methylphenidate with reference to OROS methylphenidate in ADHD [poster]. 18th Annual US Psychiatric and Mental Health Congress. Las Vegas, USA (November 7-10 2005) 205.
32. SWANSON JM, WIGAL SB, WIGAL T et al.: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics (2004) 113(3 Pt 1):e206-e216.
33. SILVA R, MUNIZ R, PESTREICH LK et al.: Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in a laboratory classroom setting. J. Child Adolesc. Psychopharmacol. (2005) 15(4):637-654.
34. LOPEZ F, SILVA R, PESTREICH L, MUNIZ R: Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr. Drugs. (2003) 5(8):545-555.
35. STEELE M, WEISS M, SWANSON J et al.: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in ADHD. Can. J. Clin. Pharmacol. (2006) 13(1):e50-e62.
36. SWANSON J: School-based Assessments and Interventions for ADD students. K.C. Publishing, Irvine, CA, USA (1992).
37. MTA COOPERATIVE GROUP: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up:24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics (2004) 113(4):754-761.
38. MARKOWITZ JS, STRAUGHN AB, PATRICK KS et al.: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet. (2003) 42(4):393-401.
39. WIGAL SB, GUPTA S, GUINTA D, SWANSON JM: Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol. Bull. (1998) 34(1):47-53.
40. KRAMER WG, READ SC, TRAN BV et al.: Pharmacokinetics of mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr. (2005) 10(Suppl 15):6-13.
41. TULLOCH SJ, ZHANG Y, MCLEAN A, WOLF KN: SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy (2002) 22(11):1405-1415.
42. MCGOUGH JJ, BIEDERMAN J, GREENHILL LL et al.: Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(6):684-691.
43. BIEDERMAN J, LOPEZ FA, BOELLNER SW, CHANDLER MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 110(2 Pt 1):258-266.
44. MCCRACKEN JT, BIEDERMAN J, GREENHILL LL et al.: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(6):673-683.
45. SPENCER TJ, BIEDERMAN J, WILENS TE: Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr. (2005) 10(Suppl. 15):14-21.
46. WEISLER RH, BIEDERMAN J, SPENCER TJ et al. ON BEHALF OF THE SLI381.303 STUDY GROUP: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. (2006) 11(8):625-639.
47. SPENCER TJ, WILENS TE, BIEDERMAN J et al.: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. (2006) 28(2):266-279.
48. BIEDERMAN J, SPENCER TJ, WILENS TE et al.: Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. (2005) 10(12 Suppl. 20):16-25.
49. MCGOUGH JJ, BIEDERMAN J, WIGAL SB et al.: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(6):530-538.
50. GOODMAN DW, GINSBERG L, WEISLER RH et al.: An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QUEST) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. (2005) 10(12 Suppl. 20):26-34.
51. WEISLER RH, BIEDERMAN J, SPENCER TJ, WILENS TE: Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. (2005) 10(12 Suppl. 20):35-43.
52. Spansule® Prescribing Information: GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
53. JAMES RS, SHARP WS, BASTAIN TM et al.: Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(11):1268-1276.
54. MONCRIEF S, CURTISS S, KRISHNAN S: Pharmacokinetics of NRP104 (lisdexamfetamine dimesylate) following administration of a single intranasal, intravenous, or oral dose in rats [poster]. 58th Institute on Psychiatric Services. New York, NY, USA (6 October 2006) 160.
55. LOPEZ FA, BOELLNER SW, CHILDRESS A, KRISHNAN S, BIEDERMAN J: Overall improvement of children with ADHD with lisdexamfetamine dimesylate (LDX; NRP104) and MAS XR [poster]. U.S. Psychiatric & Mental Health Congress. New Orleans, LA, USA (16 November 2006) 108.
56. JASINSKI D, KRISHNAN S: Abuse liability of intravenous lisdexamfetamine (LDX; NRP104) [poster]. 58th Institute on Psychiatric Services, New York, NY, USA. (6 October 2006) 169.
57. Strattera® Prescribing Information: Eli Lilly and Company, Indianapolis, IN, USA (2006).
58. WITCHER JW, LONG A, SMITH B et al.: Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. (2003) 13(1):53-63.
59. MICHELSON D, ADLER L, SPENCER T et al.: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry (2003) 53(2):112-120.
60. SPENCER T, BIEDERMAN J, WILENS T et al.: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry (1998) 155(5):693-695.
61. SPENCER T, HEILIGENSTEIN JH, BIEDERMAN J et al.: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63(12):1140-1147.
62. MICHELSON D, ALLEN AJ, BUSNER J et al.: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry (2002) 159(11):1896-1901.
63. WEISS M, TANNOCK R, KRATOCHVIL C et al.: A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44(7):647-655.
64. KELSEY DK, SUMNER CR, CASAT CD et al.: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics (2004) 114(1):e1-e8.
65. MICHELSON D, FARIES D, WERNICKE J et al.: Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics (2001) 108(5):e83.
66. ADLER LA, SPENCER TJ, MILTON DR et al.: Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J. Clin. Psychiatry (2005) 66(3):294-299.
67. KRATOCHVIL CJ, HEILIGENSTEIN JH, DITTMANN R et al.: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(7):776-784.
68. KEMNER JE, STARR HL, CICCONE PE et al.: Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv. Ther. (2005) 22(5):498-512.
69. MCGOUGH JJ, WIGAL SB, BIEDERMAN J et al.: Comparative efficacy of amphetamine and atomoxetine by symptom severity [poster]. 158th American Psychiatric Association Annual Meeting, Atlanta, GA, USA. (21-26 May 2005) NR534.
70. BIEDERMAN J, WIGAL SB, SPENCER TJ et al.: A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin. Ther. (2006) 28(2):280-293.
71. WIGAL SB, MCGOUGH JJ, MCCRACKEN JT et al.: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/ hyperactivity disorder. J. Atten. Disord. (2005) 9(1):275-289.
72. WERNICKE JF, KRATOCHVIL CJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry (2002) 63(Suppl. 12):50-55.
73. KEMNER JE, LAGE MJ: Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann. Gen. Psychiatry (2006) 5:5.
74. LAGE M, HWANG P: Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J. Child Adolesc. Psychopharmacol. (2004) 14(4):575-581.
75. THIRUCHELVAM D, CHARACH A, SCHACHAR RJ: Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(8):922-928.
76. CHRISTMAN AK, FERMO JD, MARKOWITZ JS: Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy (2004) 24(8):1020-1036.
77. SIMPSON D, PLOSKER GL: Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs (2004) 18(6):397-406.